1 / 6

OX-40 Receptor Agonist Therapeutics Pipeline Analysis - Clinical Trials & Results, Patent, Collaboration, and Other Deve

OX-40 Receptor Agonist Therapeutics Pipeline Products Under Drug Profile Includes Product Description & Developmental Activities, Licensing and Collaboration Details .

NidhiNehani
Download Presentation

OX-40 Receptor Agonist Therapeutics Pipeline Analysis - Clinical Trials & Results, Patent, Collaboration, and Other Deve

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. OX-40 Receptor Emerging as a Novel Target in Cancer Immunotherapy

  2. OX-40 Receptor Agonist Therapeutics OX-40 receptor agonist therapeutics pipeline in 2017 The study analyzed that the OX-40 receptor agonist therapeutics pipeline comprises approximately nine drug candidates in different stages of development. OX-40 is a costimulatory receptor that binds to its only known ligand, OX-40L, initiating cellular signaling events required for full activation of T cells following their recognition of a foreign antigen. OX-40 agonists mimic the effect of OX-40L, and boost the OX-40 signaling, and thereby leads to the suppression of the anti-tumor immune response in cancer patients. OX-40 agonists in combination with checkpoint immunotherapies, surgical resection, and radiotherapy has demonstrated promising results for the treatment of cancer patients. Access Report Summary with Detailed TOC on “OX-40 Receptor Agonist Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments” at: https://www.psmarketresearch.com/market-analysis/ox40-receptor-agonist-therapeutics-pipeline

  3. OX-40 Receptor Agonist Therapeutics Insights on procedure segments According to the research findings, most of the drug candidates of OX-40 receptor agonist therapeutics pipeline are being developed as a monoclonal antibody. Maximum drugs being developed as monoclonal antibody Most of the companies are focused on developing their drug candidates as monoclonal antibodies in the OX-40 receptor agonist therapeutics pipeline. Monoclonal antibodies are homogenous and consistent. Also, they can be renewably generated once a suitable hybridoma is developed and are highly sensitive to small changes in both salt concentration and ph.

  4. OX-40 Receptor Agonist Therapeutics Various collaborations for OX-40 receptor agonist drug development In November 2015, GlaxoSmithKline plc and Merck & Co., Inc. entered into a collaboration to initiate the Phase I clinical trial designed to evaluate GSK3174998 as monotherapy in combination with Merck’s anti-PD-1 therapy, Keytruda (pembrolizumab). Some of the key players developing drugs as OX-40 receptor agonist for the treatment of various indications include MedImmune, LLC, Agenus Inc., Pfizer Inc., GlaxoSmithKline plc and others.

  5. OX-40 Receptor Agonist Therapeutics Download report sample at: https://www.psmarketresearch.com/market-analysis/ox40-receptor-agonist-therapeutics-pipeline/report-sample

  6. GET IN TOUCH THANK YOU! For information regarding permissions and other queries Kindly write to: US/Canada Toll-Free: 1-888-778-7886

More Related